#Taiwan #Taichung #China Medical Uni #National Innovation #Healthcare Awards

CMU's Unprecedented Achievement at the 2024 Taiwan National Innovation Awards

On January 12, 2025, the China Medical University (CMU) and its affiliated healthcare system marked a historic milestone by winning an astonishing 17 awards at the 2024 Taiwan National Innovation Awards. This event is considered one of the highest honors in the biomedical and healthcare sectors, recognizing groundbreaking advancements that shape the future of these fields. CMU took home awards across three distinct categories, including two Corporate Innovation Awards, six Academic-Research Innovation Awards, and nine Clinical Innovation Awards.

The accolades underscore CMU's role as a pioneer in biotechnology, smart healthcare, and innovative medical devices. One of the standout innovations that contributed to this success is the revolutionary CAR001 cell therapy, developed by CMU's spin-off company, Ever Supreme Bio Technology. This cutting-edge treatment utilizes both allogeneic CAR and BiTE-GDT technologies to effectively target solid tumors like never before.

Using advanced artificial intelligence, CMU’s research team identified HLA-G as a crucial target, leading to the creation of the CAR001 (CAR-T) technique. In preclinical trials, this innovative therapy achieved an impressive 90% tumor eradication rate, with findings published in leading medical journals. Furthermore, CAR001 has gained Phase I and IIa clinical trial approvals in both Taiwan and the United States, marking a significant step towards widespread clinical application.

Apart from these innovations, CMU presented its groundbreaking efforts during the exciting “Demo Day” segment of the awards, where premier teams showcased their technologies to prominent Taiwanese investors for immediate feedback. Ever Supreme Bio Technology was one of the top ten teams highlighted, reinforcing the global potential and competitiveness of CMU’s technology.

CMU and Healthcare System's achievements extend beyond advanced therapies. Their innovative use of artificial intelligence enhances numerous critical areas, including drug discovery, myocardial infarction treatment, infection and sepsis management, remote dialysis, image analysis, and medical education.

Furthermore, they have broken new ground with exosome-based technology, offering promising solutions for patients suffering from cancer and neurodegenerative diseases like Parkinson’s. This cutting-edge targeted exosome delivery system significantly improves treatment outcomes, providing new hope for those dealing with conditions traditionally viewed as unmanageable.

As an integral hub of innovation, CMU exemplifies the marriage of unparalleled research excellence and international collaboration. By partnering with premier academic and medical institutions globally, CMU is accelerating the clinical integration of its revolutionary technologies. Their steadfast commitment to enhancing biomedical innovation and smart healthcare is transforming patient treatment and marking a significant, lasting impact on the global healthcare landscape.

The future of healthcare shines brighter each day—and with organizations like CMU leading the charge, ambitious transformations in patient care and medical technology are well on their way.